drug
(amivantamab + hyaluronidase (human recombinant))
Marketedupdated 6mo agoby $JNJ JOHNSON & JOHNSON
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5indications
investigational
NSCLC
all catalysts(2)
News(1)
- FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell CarcinomaThe U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and n…fda_press · 5d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that